Search

Your search keyword '"Ch'ng, Sydney"' showing total 528 results

Search Constraints

Start Over You searched for: Author "Ch'ng, Sydney" Remove constraint Author: "Ch'ng, Sydney"
528 results on '"Ch'ng, Sydney"'

Search Results

1. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

3. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

4. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

8. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort

9. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

14. Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy

24. A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).

26. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

30. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

31. Quality of Life Outcomes in Patients Receiving Dental Implants in Vascularised Bone Flaps for Mandibular Reconstruction

32. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

38. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

43. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

44. Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe

49. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

50. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Catalog

Books, media, physical & digital resources